<DOC>
	<DOCNO>NCT01989455</DOCNO>
	<brief_summary>Single center , randomize , double-blind , placebo-controlled , adaptive sequential ascending-dose study evaluation safety , tolerability , pharmacokinetics single dos deferiprone administer intravenous infusion healthy male female . A bioavailability comparison include .</brief_summary>
	<brief_title>A Blinded , Placebo-Controlled Study Safety Pharmacokinetics Single Doses Intravenous Deferiprone Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Main 1 . Healthy adult male female , least 18 year old old 50 year . 2 . Body weight least 60kg . 3 . Body Mass Index ( BMI ) ≥ 18.50 ≤ 30.00 kg/m2 4 . Medically healthy clinically insignificant screen result ( e.g. , laboratory profile , medical history , ECG , vital sign , physical examination . 5 . Non exsmoker ( someone completely stop smoke 6 month study start ) 6 . For female , negative result serum pregnancy test . Main 1 . Absolute neutrophil count ( ANC ) &lt; 1.5x10^9/L . 2 . History presence hypersensitivity deferiprone relate product . 3 . History presence gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug . 4 . Presence significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease . 5 . Any history tuberculosis ( TB ) prophylaxis TB . 6 . Suicidal tendency , history seizure , head trauma coma craniotomy/trepanation , state confusion relevant psychiatric disease . 7 . Inadequate venous access either arm . 8 . Presence outofrange cardiac interval clinically significant ECG abnormality ( PR &lt; 110 msec &gt; 220 msec , QRS &lt; 60 msec &gt; 119 msec , QTcB &gt; 450 msec male &gt; 460 msec female ) . 9 . Use acetaminophen , acetylsalicylic acid ( ASA ) , nonsteroidal antiinflammatory drug ( NSAIDs ) previous 7 day study start . 10 . Use enzymemodifying drug , include strong inhibitor P450 ( CYP ) enzymes cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem , HIV antiviral OR strong inducer CYP enzyme : barbiturate , carbamazepine , glucocorticoid , phenytoin , rifampin , St. John 's wart within 28 day prior study start . 11 . Maintenance therapy drug , significant history drug dependency alcohol abuse . 12 . Had clinically significant illness 28 day prior study start . 13 . Receipt investigational product another clinical trial within 28 day prior prior study start . 14 . Enrolment previous cohort study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>DFP</keyword>
	<keyword>L1</keyword>
</DOC>